Drug Index


Mechanism :

Darunavir is a HIV protease inhibitor which prevents HIV replication by binding to the enzyme's active site, thereby preventing the dimerization and the catalytic activity of the HIV-1 protease. Darunavir selectively inhibits the cleavage of HIV encoded Gag-Pol polyproteins in virus-infected cells, which prevents the formation of mature infectious virus particles. Structural analyses suggest that the close contact that darunavir has with the main chains of the protease active site amino acids (Asp-29 and Asp-30) is an important contributing factor to its potency and wide spectrum of activity against multi-protease inhibitor resistant HIV-1 variants. Darunavir can also adapt to the changing shape of a protease enzyme because of its molecular flexibility. Darunavir is known to bind to two distinct sites on the enzyme: the active site cavity and the surface of one of the flexible flaps in the protease dimer.

Indication :

  • HIV-1 infection

Contraindications :

Co-administration of PREZISTA/ritonavir is contraindicated with drugs that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/or life-threatening events (narrow therapeutic index).

Dosing :

Under 3 years or under 10 kg: Safety and efficacy not established.
10 kg to <15 kg:
20 mg/kg orally twice a day (plus ritonavir 3 mg/kg twice a day).
15 kg to <30 kg:
375 mg orally (+ ritonavir 50 mg) twice a day.
30 kg to <40 kg:
450 mg orally (+ ritonavir 60 mg) twice a day.
≥40 kg:
600 mg orally (+ ritonavir 100 mg) twice a day.

Adverse Effect :

Increased total cholesterol, increased triglycerides, diarrhea, pain, nausea, vomiting, acute pancreatitis, dyspepsia, flatulence, hepatotoxicity, hypersensitivity reactions, Diabetes mellitus, myalgia, osteonecrosis, abnormal dreams, angioedema, pruritus, Stevens-Johnson Syndrome, urticaria.

Interaction :

Certain azole fungal medications (ketoconazole, itraconazole, voriconazole), boceprevir, efavirenz, pimozide, telaprevir: May decrease the effectiveness of hormonal birth control such as pills, patch, or ring. This could cause pregnancy.

Renal Dose :

Dose in Renal Impairment GFR (mL/min)
20-50Dose as in normal renal function
10-20Dose as in normal renal function
<10Dose as in normal renal function

Dose in Patients undergoing Renal Replacement Therapies
CAPDUnlikely to be dialysed. Dose as in normal renal function
HDUnlikely to be dialysed. Dose as in normal renal function
HDF/High fluxUnlikely to be dialysed. Dose as in normal renal function
CAV/VVHDUnlikely to be dialysed. Dose as in normal renal function

Hepatic Dose :

Avoid in severe hepatic impairment.
01/21/2024 10:33:22 Darunavir
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0